Bronchogen Molecular Structure & Chemical Properties

Bronchogen peptide represents one of the most extensively studied bioregulatory tetrapeptides in respiratory research, with investigations examining its effects on bronchial epithelium function and tissue-specific gene expression. Originally developed through the Khavinson peptide research program at the Saint Petersburg Institute of Bioregulation and Gerontology in the 1990s, this four-amino acid peptide has demonstrated remarkable tissue specificity for lung tissue and an unusual ability to penetrate cell membranes and interact directly with DNA. Unlike most peptides that are rapidly degraded or act solely through cell surface receptors, Bronchogen’s compact structure enables it to enter the nucleus where it binds to specific DNA sequences, making it a unique subject of investigation in epigenetic regulation and tissue-specific bioregulation research.

Chemical Structure

2D molecular structure of Bronchogen tetrapeptide

Technical Specifications

The peptide’s compact four-amino acid structure contains two acidic residues (glutamic acid and aspartic acid), contributing to its negative charge at physiological pH and enabling specific electrostatic interactions with DNA bases. This structural characteristic appears fundamental to its DNA-binding properties and tissue-specific regulatory effects.

Bronchogen Mechanism of Action

Bronchogen peptide exerts its biological effects through direct interaction with genomic DNA rather than traditional receptor-mediated pathways. Current research suggests that DNA binding at specific sequences serves as the primary mechanism of action, with the peptide demonstrating preferential binding to CTG-rich motifs and CNG sites associated with cytosine methylation in mammalian genomes. This unusual mechanism distinguishes Bronchogen from conventional peptide therapeutics and positions it as a potential epigenetic modulator.

Primary Molecular Mechanisms

DNA Stabilization – Thermodynamic Effects

Research using differential scanning microcalorimetry has demonstrated that Bronchogen significantly increases DNA melting temperature by approximately 3.1 degrees C in calf thymus and mouse liver DNA preparations[1]. This stabilization indicates:

• Enhanced resistance to thermal denaturation of DNA double helix
• Potential reduction in spontaneous DNA strand separation
• Increased genomic stability under cellular stress conditions
• Protection against oxidative damage to nucleic acids

The thermodynamic stabilization occurs within a specific molar ratio range, suggesting saturable binding sites on DNA molecules rather than non-specific aggregation effects².

Gene Expression Modulation – Transcription Factor Regulation

Bronchogen influences the expression of multiple genes involved in bronchial epithelial cell differentiation and function³. Key regulatory effects include:

• Upregulation of NKX2-1, SCGB1A1, SCGB3A2 (lung-specific transcription factors and secretoglobins)
• Activation of FOXA1 and FOXA2 (forkhead box transcription factors critical for respiratory development)
• Enhanced expression of Hoxa3 (developmental transcription factor) by 1.4-1.7 fold in bronchial epithelial cells
• Modulation of MUC4, MUC5AC (mucin genes) and surfactant protein genes

These transcription factor changes appear more pronounced in aged cell cultures compared to young cultures, suggesting a potential role in counteracting age-related decline in bronchial function.

DNA Sequence-Specific Binding

Investigations using fluorescence-labeled peptides and oligonucleotide binding studies have revealed that Bronchogen preferentially binds to deoxyribooligonucleotides containing CNG sequencesâ´. This binding:

• Occurs at the major groove of DNA at guanine N7 sites
• Does not visibly distort the double helix structure
• Shows preference for CTG-containing motifs
• May influence local chromatin structure and accessibility

The interaction involves non-covalent forces including hydrogen bonding and van der Waals interactions with nitrogen bases on both DNA strandsâµ.

Anti-Inflammatory Pathway Modulation

Studies in chronic obstructive pulmonary disease (COPD) models demonstrate that Bronchogen modulates inflammatory signaling pathwaysâ¶:

• Normalization of pro-inflammatory cytokine profiles (TNF-alpha, IL-6)
• Reduction in neutrophilic inflammation in bronchoalveolar space
• Decreased activity of pro-inflammatory enzymes
• Modulation of COX-2 and antioxidant system genes (SOD, HSP70)

Cell Proliferation and Differentiation Signaling

Research in cell culture models indicates effects on proliferation-associated pathwaysâ·:

• Increased expression of Ki-67 (proliferation marker)
• Enhanced expression of Mcl-1 (anti-apoptotic protein)
• Modulation of p53 pathway components
• Effects on CD79 and NOS-3 protein synthesis

Bronchogen Research Applications & Key Findings

Respiratory Pathology Research

Chronic Obstructive Pulmonary Disease Models

Extensive research in rat models of COPD induced by nitrogen dioxide exposure has examined Bronchogen’s effects on bronchial epithelium remodelingâ¸. Key findings include:

• Elimination of goblet cell hyperplasia – reduction in excessive mucus-producing cell populations
• Restoration of ciliated epithelial cells – recovery of the mucociliary clearance apparatus
• Prevention of squamous metaplasia in bronchial epithelium
• Reduction in lymphocytic infiltration and emphysematous changes
• Normalization of bronchial epithelial architecture after one month of treatment

Histological examinations revealed that Bronchogen-treated animals showed marked improvement in epithelial structure compared to untreated COPD models, with cellular morphology approaching that of control animalsâ¹.

Inflammatory Airway Disease Studies

Research in models of acute and chronic bronchitis has demonstrated anti-inflammatory effects¹â°:

• Decreased neutrophilic inflammation measured by cell counts in bronchoalveolar lavage fluid
• Normalization of cytokine profiles in airway fluids
• Reduced expression of pro-inflammatory mediators
• Enhanced local immune function markers

Pulmonary Fibrosis Research

Investigations in bleomycin-induced pulmonary fibrosis models have examined Bronchogen’s effects on fibrotic remodeling¹¹:

• Reduction in fibrotic changes in lung parenchyma
• Decreased collagen deposition in affected areas
• Modulation of extracellular matrix remodeling
• Preservation of normal alveolar architecture

Molecular Biology Research

DNA Interaction Studies

In vitro investigations have characterized Bronchogen’s physical interactions with DNA¹²:

• Binding affinity measurements using spectroscopic and calorimetric techniques
• Determination of binding stoichiometry and thermodynamic parameters
• Characterization of sequence preferences in oligonucleotide binding assays
• Assessment of effects on DNA secondary structure

Gene Expression Research

Cell culture studies in human bronchial epithelial cells have mapped transcriptional responses¹³:

• Time-course analysis of gene expression changes following peptide exposure
• Identification of dose-dependent transcriptional responses
• Characterization of tissue-specific versus ubiquitous gene targets
• Investigation of epigenetic modifications at target loci

Cellular Aging Research

Research examining age-related changes in bronchial epithelial cells has revealed differential responses¹â´:

• Enhanced effects in aged cell cultures (passage 14) compared to young cultures (passage 1)
• Greater fold-change in differentiation factor expression in senescent cells
• Potential role in counteracting age-related decline in respiratory function
• Implications for geroprotective mechanisms in lung tissue

Immune Function Research

Studies measuring local immunity markers in respiratory tissue¹âµ:

• Increased secretory IgA production (2-3 fold elevation in some studies) – key marker of local mucosal immunity
• Enhanced surfactant protein B levels – critical for alveolar stability and surface tension reduction
• Restoration of immune barrier function in damaged epithelium
• Support for first-line defense mechanisms in airways

Bronchogen Pharmacokinetics & Metabolism

Absorption & Distribution

The pharmacokinetic profile of Bronchogen in mammals remains incompletely characterized in published literature. Based on the peptide’s physicochemical properties and studies of related short peptides¹â¶:

• Membrane penetration – the tetrapeptide’s compact structure and specific amino acid composition enable cell membrane crossing
• Nuclear localization demonstrated in cell culture studies using fluorescence-labeled variants
• Tissue-specific accumulation suggested by selective effects on lung versus other tissues
• Likely absorption from various administration routes based on indirect functional evidence

The mechanism enabling Bronchogen’s apparent tissue specificity despite its small size and potential for broad distribution remains under investigation.

Metabolism & Elimination

Specific metabolic pathways for Bronchogen have not been comprehensively characterized in published peer-reviewed literature¹â·:

• Peptidase degradation – likely susceptible to dipeptidyl peptidases and other proteolytic enzymes in plasma and tissues
• No published data on plasma half-life in any species
• Metabolic fate of constituent amino acids presumed to enter normal metabolic pools
• Duration of biological effects appears to exceed expected plasma residence time

A significant knowledge gap exists regarding the relationship between peptide pharmacokinetics and the prolonged biological effects observed in animal studies (effects persisting days after administration).

Excretion Pathways

Elimination routes have not been definitively established in published studies¹â¸:

• Renal elimination likely for small peptide fragments
• Hepatic metabolism may contribute to clearance
• No accumulation reported in repeated-dose animal studies
• Excretion kinetics require systematic investigation

The lack of detailed pharmacokinetic data represents a major limitation in translating preclinical findings to potential clinical applications.

Bronchogen Research Protocols & Administration

Dosing in Published Research

Research investigations have employed various Bronchogen doses depending on species, model, and experimental objectives¹â¹:

• Rat COPD models: 1 month of daily administration (specific doses not uniformly reported in available literature)
• Cell culture studies: Concentrations ranging from nanomolar to micromolar levels
• In vitro DNA binding studies: Molar ratios of peptide to DNA nucleotides varied to characterize binding parameters

Most published animal studies report treatment duration (weeks to months) rather than precise per-kilogram dosing, reflecting the investigational nature of this peptide and its complex mechanisms.

Important: These are experimental protocols used in research models and cannot be extrapolated to other species due to profound differences in peptide metabolism, tissue distribution, cellular receptor expression, proteolytic enzyme activity, and pharmacokinetic parameters. Species-specific factors fundamentally influence both peptide activity and safety profiles. Extrapolation from rodent studies to humans requires extensive pharmacokinetic studies and controlled clinical trials.

Administration Routes in Research

Multiple delivery methods have been investigated in experimental models²â°:

• Oral administration – used in some Russian clinical practice contexts (not peer-reviewed publications), capsule formulations
• Subcutaneous injection – employed in some animal study protocols for systemic delivery
• Intraperitoneal injection – used in certain rodent experiments
• Direct tissue application – investigated in some in vitro and ex vivo studies
• Cell culture exposure – dissolution in culture medium for mechanistic studies

Common Model Organisms

Bronchogen has been studied across multiple experimental systems²¹:

• Rats – Primary animal model (Wistar strain most common); COPD induction via nitrogen dioxide, pulmonary fibrosis models
• Mice – Used in some molecular biology and aging studies
• Cell cultures – Human bronchial epithelial cells (multiple passage numbers representing different ages), HeLa cells for nuclear penetration studies
• In vitro systems – Purified DNA from calf thymus and mouse liver for binding characterization, oligonucleotide binding assays

Research Limitations & Regulatory Status

Critical Gaps in Current Evidence

Despite several decades of investigation within the Khavinson peptide research program, Bronchogen faces substantial translational barriers that limit its research utility and prevent clinical application.

Lack of Human Clinical Data

The most significant limitation is the absence of published human clinical trials meeting international standards:

• No peer-reviewed human clinical trials published in indexed scientific journals
• No Phase I, II, or III studies registered in international clinical trial databases (ClinicalTrials.gov, EudraCT)
• Human safety profile not established through controlled studies
• Optimal human dosing, bioavailability, and pharmacokinetics unknown
• Long-term effects in humans completely unstudied

While Russian clinical practice materials reference use of Bronchogen-containing formulations, these lack the controlled study design, independent peer review, and data transparency required for scientific validation.

Mechanistic Understanding Gaps

Fundamental aspects of Bronchogen’s mechanism require clarification:

• Precise DNA binding sequences – consensus motif incompletely defined
• Functional consequences of DNA binding on transcription unclear
• Mechanism conferring tissue specificity not fully elucidated
• Whether observed effects are direct or via intermediate signaling pathways uncertain
• Relationship between in vitro DNA binding and in vivo biological effects requires validation

Pharmacokinetic Deficiencies

Critical pharmacokinetic parameters remain uncharacterized:

• Plasma half-life not reported in any species
• Bioavailability after oral administration not quantified
• Tissue distribution and elimination kinetics unstudied
• Drug-drug interaction potential unknown
• Effects of renal or hepatic impairment not investigated

Long-Term Safety Considerations

Essential safety questions remain unanswered:

• Chronic use effects beyond several weeks unstudied even in animals
• Potential for unintended gene expression alterations with prolonged exposure unknown
• Cancer risk assessment not conducted (given DNA-binding mechanism)
• Reproductive and developmental toxicity inadequately characterized
• Immunogenicity potential in humans uninvestigated

Regulatory & Competitive Sport Status

FDA Position

Bronchogen has not received FDA approval or recognition for any indication:

• Not approved as a drug for human or veterinary use
• Not recognized as Generally Recognized as Safe (GRAS) for dietary supplements
• Not legally available for compounding in clinical pharmacy practice in the United States
• No established therapeutic use basis in US regulatory framework
• Not classified as a pharmaceutical ingredient by FDA

The FDA has not issued specific guidance documents on Bronchogen, but as an unapproved new drug substance, marketing for human use would violate federal regulations.

WADA Status

Bronchogen’s status under World Anti-Doping Agency regulations:

• Potential classification under Section S0 (Non-Approved Substances) due to lack of regulatory approval
• May be considered a prohibited substance if it demonstrates performance-enhancing potential
• No Therapeutic Use Exemptions available for substances lacking approved medical use
• Athletes should consult WADA guidelines and their sport’s anti-doping authority

The lack of human clinical data and regulatory approval in any jurisdiction worldwide limits its availability for legitimate medical or research use.

Research Classification: Bronchogen is available only for in vitro laboratory research use. It is not intended for human consumption, medical use, diagnostic purposes, or veterinary applications. All research must be conducted under appropriate ethical oversight, institutional review board approval where applicable, and in compliance with local regulations governing research with bioactive compounds.

Saint Petersburg Institute of Bioregulation and Gerontology, Saint Petersburg, Russia

Professor Vladimir Khavinson was the principal investigator and developer of Bronchogen along with the broader family of peptide bioregulators bearing his name. Beginning in the 1970s at the Soviet military medical research facilities, he pioneered the investigation of short regulatory peptides extracted from various organs, later synthesizing these sequences for research and potential therapeutic applications.

His research contributions specific to Bronchogen include:

• Development and characterization of the AEDL tetrapeptide sequence from bronchial tissue studies
• Extensive investigations of bronchopulmonary bioregulation and tissue-specific peptide effects
• Research on DNA-binding properties of short peptides and their gene regulatory functions
• Studies on aging-related changes in bronchial epithelium and peptide interventions
• Development of methodologies for peptide bioregulator research and applications

Professor Khavinson published over 775 scientific works and held 196 patents across multiple countries during his career. He served as Treasurer of the European region of the International Association of Gerontology and Geriatrics and introduced the scientific specialty of “Gerontology and Geriatrics” in the Russian Federation. He passed away in January 2024, leaving a complex scientific legacy that includes pioneering work on peptide bioregulators alongside questions about the reproducibility and international validation of some findings.

Disclaimer: This spotlight is provided for educational purposes to acknowledge scientific contributions to Bronchogen research. Cenexa Labs has no affiliation with Professor Khavinson, his estate, or the Saint Petersburg Institute of Bioregulation and Gerontology, and this information does not constitute an endorsement of any products or services. The inclusion of this information reflects historical attribution of research efforts and does not imply validation of all research claims or clinical applications.

References

1. Monaselidze, J.R., Khavinson, V.K., Gorgoshidze, M.Z., Khachidze, D.G., Lomidze, E.M., Jokhadze, T.A., & Lezhava, T.A. (2011). Effect of the peptide bronchogen (Ala-Asp-Glu-Leu) on DNA thermostability. Bulletin of Experimental Biology and Medicine, 150(3), 375-377. PubMed
   
2. Morozova, E.A., Lin’kova, N.S., Khavinson, V.K., Soloviev, A.Y., & Kasyanenko, N.A. (2017). In vitro interaction of the AEDL peptide with DNA. Journal of Structural Chemistry, 58(2), 420-424.
3. Khavinson, V.K., Tendler, S.M., Vanyushin, B.F., Kasyanenko, N.A., Kvetnoy, I.M., Linkova, N.S., Ashapkin, V.V., Polyakova, V.O., Basharina, V.M., & Bernadotte, A. (2014). Peptide regulation of gene expression and protein synthesis in bronchial epithelium. Lung, 192(5), 781-791. PubMed
   
4. Fedoreyeva, L.I., Kireev, I.I., Khavinson, V.K., & Vanyushin, B.F. (2011). Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Moscow), 76(11), 1210-1219. PubMed
   
5. Morozova, E.A., Lin’kova, N.S., Khavinson, V.K., Soloviev, A.Y., & Kasyanenko, N.A. (2017). In vitro interaction of the AEDL peptide with DNA. Journal of Structural Chemistry, 58(2), 420-424.
6. Titova, O.N., Kuzubova, N.A., Lebedeva, E.S., Preobrazhenskaya, T.N., Surkova, E.A., & Dvorakovskaya, I.V. (2017). Antiinflammatory and regenerative effect of peptide therapy in the model of obstructive lung pathology. Rossiiskii Fiziologicheskii Zhurnal Imeni I.M. Sechenova, 103(2), 201-208. PubMed
   
7. Khavinson, V.K., Tendler, S.M., Vanyushin, B.F., Kasyanenko, N.A., Kvetnoy, I.M., Linkova, N.S., Ashapkin, V.V., Polyakova, V.O., Basharina, V.M., & Bernadotte, A. (2014). Peptide regulation of gene expression and protein synthesis in bronchial epithelium. Lung, 192(5), 781-791. PubMed
   
8. Kuzubova, N.A., Lebedeva, E.S., Dvorakovskaya, I.V., Surkova, E.A., Platonova, I.S., & Titova, O.N. (2015). Modulating effect of peptide therapy on the morphofunctional state of bronchial epithelium in rats with obstructive lung pathology. Bulletin of Experimental Biology and Medicine, 159(5), 685-688. PubMed
   
9. Kuzubova, N.A., Lebedeva, E.S., Dvorakovskaya, I.V., Surkova, E.A., Platonova, I.S., & Titova, O.N. (2015). Modulating effect of peptide therapy on the morphofunctional state of bronchial epithelium in rats with obstructive lung pathology. Bulletin of Experimental Biology and Medicine, 159(5), 685-688. PubMed
   
10. Titova, O.N., Kuzubova, N.A., Lebedeva, E.S., Preobrazhenskaya, T.N., Surkova, E.A., & Dvorakovskaya, I.V. (2017). Antiinflammatory and regenerative effect of peptide therapy in the model of obstructive lung pathology. Rossiiskii Fiziologicheskii Zhurnal Imeni I.M. Sechenova, 103(2), 201-208. PubMed
    
11. Khavinson, V.K., Tendler, S.M., Vanyushin, B.F., Kasyanenko, N.A., Kvetnoy, I.M., Linkova, N.S., Ashapkin, V.V., Polyakova, V.O., Basharina, V.M., & Bernadotte, A. (2014). Peptide regulation of gene expression and protein synthesis in bronchial epithelium. Lung, 192(5), 781-791. PubMed
    
12. Morozova, E.A., Lin’kova, N.S., Khavinson, V.K., Soloviev, A.Y., & Kasyanenko, N.A. (2017). In vitro interaction of the AEDL peptide with DNA. Journal of Structural Chemistry, 58(2), 420-424.
13. Khavinson, V.K., Tendler, S.M., Vanyushin, B.F., Kasyanenko, N.A., Kvetnoy, I.M., Linkova, N.S., Ashapkin, V.V., Polyakova, V.O., Basharina, V.M., & Bernadotte, A. (2014). Peptide regulation of gene expression and protein synthesis in bronchial epithelium. Lung, 192(5), 781-791. PubMed
    
14. Khavinson, V.K., Linkova, N.S., Polyakova, V.O., Kheifets, O.V., Tarnovskaya, S.I., & Kvetnoy, I.M. (2012). Peptides tissue-specifically stimulate cell differentiation during their aging. Bulletin of Experimental Biology and Medicine, 153(1), 148-151. PubMed
    
15. Kuzubova, N.A., Lebedeva, E.S., Dvorakovskaya, I.V., Surkova, E.A., Platonova, I.S., & Titova, O.N. (2015). Modulating effect of peptide therapy on the morphofunctional state of bronchial epithelium in rats with obstructive lung pathology. Bulletin of Experimental Biology and Medicine, 159(5), 685-688. PubMed
    
16. Khavinson, V.K., Popovich, I.G., Linkova, N.S., Mironova, E.S., & Ilina, A.R. (2021). Peptide regulation of gene expression: A systematic review. Molecules, 26(22), 7053. PubMed
    
17. Khavinson, V.K. (2005). Gerontological aspects of genome peptide regulation. Basel, Switzerland: Karger AG.
18. Khavinson, V.K. (2002). Peptides and ageing. Neuroendocrinology Letters, 23(Suppl 3), 11-144. PubMed
    
19. Kuzubova, N.A., Lebedeva, E.S., Dvorakovskaya, I.V., Surkova, E.A., Platonova, I.S., & Titova, O.N. (2015). Modulating effect of peptide therapy on the morphofunctional state of bronchial epithelium in rats with obstructive lung pathology. Bulletin of Experimental Biology and Medicine, 159(5), 685-688. PubMed
    
20. Titova, O.N., Kuzubova, N.A., Lebedeva, E.S., Preobrazhenskaya, T.N., Surkova, E.A., & Dvorakovskaya, I.V. (2017). Antiinflammatory and regenerative effect of peptide therapy in the model of obstructive lung pathology. Rossiiskii Fiziologicheskii Zhurnal Imeni I.M. Sechenova, 103(2), 201-208. PubMed
    
21. Khavinson, V.K., Linkova, N.S., Polyakova, V.O., Kheifets, O.V., Tarnovskaya, S.I., & Kvetnoy, I.M. (2012). Peptides tissue-specifically stimulate cell differentiation during their aging. Bulletin of Experimental Biology and Medicine, 153(1), 148-151. PubMed
    

All references open in new window. These citations are provided for educational and research purposes only. This information is not intended to diagnose, treat, cure, or prevent any disease. Bronchogen is intended for laboratory research use only.